Today: 11 April 2026

Real-time market monitoring

Browse Category

Pharmaceuticals 7 December 2025 - 10 December 2025

Eli Lilly (LLY) Stock Near $1 Trillion: Zepbound Price Cuts, New $6B Plant and 2026 Dividend Hike – Is It Still a Buy?

Eli Lilly shares traded near $980 midday Monday, after briefly surpassing $1,050 and becoming the first healthcare firm valued above $1 trillion. Q3 revenue rose 54% to $17.6 billion, fueled by Zepbound and Mounjaro sales topping $10 billion. The company announced a $6 billion Alabama plant for its oral weight-loss drug and completed its Adverum Biotechnologies acquisition. LLY trades at about 49 times trailing earnings, far above big-pharma averages.

10 December 2025

NYSE:LLY·Pharmaceuticals·Stock Market

Reviva Pharmaceuticals (RVPH) Stock Today: Price, News, Forecast & Schizophrenia NDA Setup – 10 December 2025

Reviva Pharmaceuticals (RVPH) traded around $0.69 per share mid-session December 10, up 10% on the day but still down 72% over the past year. Market cap stood near $78–80 million. On December 9, call options volume spiked 458% above average as traders speculated on upcoming catalysts. The company’s lead drug, brilaroxazine, recently completed Phase 3 trials in schizophrenia.

10 December 2025

NASDAQ:RVPH·Pharmaceuticals·Stock Market

Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold

Biodexa Pharmaceuticals (NASDAQ: BDRX) closed at $4.09 on December 9, down 53.5% from the prior session, after wild swings that saw the stock trade between $4.00 and $7.60 intraday. The company is advancing a Phase 3 trial in a rare inherited cancer syndrome and exploring new financing. Its float remains under 670,000 ADSs, fueling extreme volatility. Market cap stands near $5.5 million.

10 December 2025

NASDAQ:BDRX·Pharmaceuticals·Stock Market

GSK Stock on 10 December 2025: FDA Orphan-Drug Win, New Cancer Deal and What It Means for Investors

The US FDA granted Orphan Drug Designation to GSK’s experimental lung cancer therapy risvutatug rezetecan on December 10. GSK shares traded near 1,780 pence in London, up about 29% over 12 months. The drug targets small-cell lung cancer and has shown durable responses in early trials. GSK’s US ADR closed at $47.27, near its 52-week high.

10 December 2025

LSE:GSK·NYSE:GSK·Pharmaceuticals·Stock Market

Merck (MRK) Slides After the Bell on December 9, 2025: Keytruda Biosimilar Jitters and What to Watch Before the December 10 Open

Merck shares closed down 2.06% at $96.89 on December 9, 2025, with volume spiking to 15.3 million shares. The drop followed news that Formycon and Zydus Lifesciences will partner on a biosimilar to Merck’s top-selling cancer drug Keytruda, targeting the U.S. and Canada. Keytruda generated $29.5 billion in 2024 sales. Merck and JPMorgan were among the biggest drags on the Dow, which fell 0.8%.

10 December 2025

NYSE:MRK·Pharmaceuticals·Stock Market

Eli Lilly’s $6 Billion Huntsville Plant: 450 High‑Paying Jobs, GLP‑1 Drug Boom and Alabama’s Biggest Industrial Bet

Eli Lilly will invest over $6 billion to build a pharmaceutical manufacturing campus in Huntsville, Alabama, creating 450 permanent and 3,000 construction jobs. The 260-acre facility will produce active ingredients for small-molecule and peptide medicines, including the oral GLP-1 obesity drug orforglipron. Construction is set to begin in 2026 and finish by 2032. State officials call it Alabama’s largest-ever private industrial investment.

10 December 2025

NYSE:LLY·Pharmaceuticals

Olema Pharmaceuticals (OLMA) Stock: Latest News, Forecast & Analysis as of December 9, 2025

Olema Pharmaceuticals shares traded at $26–27 on December 9, up over 800% from their 52-week low but 12% below the recent high. The stock surged after Roche’s positive Phase 3 results for a similar breast cancer drug, triggering analyst upgrades and price target hikes. Market capitalization now stands near $2–2.2 billion. Analyst 12-month targets range from $20 to $55, with most rating the stock a strong buy.

9 December 2025

NASDAQ:OLMA·Pharmaceuticals·Stock Market

Arrowhead Pharmaceuticals (ARWR) Stock Soars on First FDA Approval, Novartis Deal and New Alzheimer’s Trial

Arrowhead Pharmaceuticals stock surged to a 52-week high of $71.5 on December 8, 2025, after securing its first FDA approval for REDEMPLO and announcing a major Novartis licensing deal. Shares traded around $69 on December 9, up over 260% year-to-date, with market value near $9.5 billion. Trading volume more than doubled typical levels. The company also began dosing in an Alzheimer’s trial.

9 December 2025

NASDAQ:ARWR·Pharmaceuticals·Stock Market

GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating

GSK shares traded near 52-week highs on December 9, 2025, with London shares at £18.05 and NYSE ADRs at $48.5, both up over 30% year-on-year. The stock surged after a Q3 earnings beat and upgraded 2025 guidance, driven by strong HIV and oncology drug sales. GSK now expects full-year sales growth of 6–7% and core EPS growth of 10–12%.

9 December 2025

LSE:GSK·NYSE:GSK·Pharmaceuticals·Stock Market

Eli Lilly (LLY) Stock After Hours on December 8, 2025: China Mounjaro Win, Dividend Hike and What to Watch Before Tuesday’s Open

Eli Lilly shares closed at $998 on December 8, down 1.3%, marking a seventh straight decline and leaving the stock about 10% below its recent high. The company reported a 15% dividend increase, secured Chinese reimbursement for Mounjaro, and saw Nobel laureate Carolyn Bertozzi return to its board. Competition and price cuts in weight-loss drugs weighed on the stock.

9 December 2025

Dividends·Earnings Reports·NASDAQ:GPCR·NYSE:JNJ·NYSE:LLY·Pharmaceuticals·Stock Market

Pfizer (PFE) Stock Today: Hemophilia Breakthrough, Metsera Deal and AI Cost Cuts – Price, Forecast and News for December 8, 2025

Pfizer shares traded near $26 on December 8, 2025, with a market cap around $148 billion and a dividend yield of 6.6–7%. The stock remains down about 36% over five years and over 50% below its December 2021 peak. New Phase 3 hemophilia data, an obesity-drug acquisition, and AI-driven cost cuts drew investor attention. Year-to-date total return is flat to slightly positive, depending on dividend inclusion.

8 December 2025

Biotechnology·NYSE:PFE·Pharmaceuticals·Stock Market

Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics shares jumped about 20% to $21.70 intraday on December 8, 2025, after new Phase 1 data for its BTK degrader bexobrutideg (NX-5948) in blood cancers was presented at the ASH Annual Meeting. The company reported an 83% response rate in relapsed/refractory CLL/SLL patients and scheduled a webcast for the evening. Volume was well above normal, with shares trading near a 52-week high.

8 December 2025

NASDAQ:NRIX·Pharmaceuticals·Stock Market

Johnson & Johnson (JNJ) Stock Outlook 2026: Talc Verdicts, Stelara Cliff and a 40% Rally – What Investors Need to Know Now

Johnson & Johnson shares traded at $202.48 on December 8, 2025, near a 52-week high and up nearly 35% over the past year. The company raised its 2025 sales guidance to $93–94 billion and EPS to about $10.80–$10.90 after beating Q2 and Q3 expectations. Analysts’ 12-month targets average just above the current price, with a consensus “Buy” rating. J&J faces Stelara patent loss, talc lawsuits, and MedTech pricing pressure in China.

8 December 2025

Financial Forecasts·NYSE:JNJ·Pharmaceuticals

Merck (MRK) Stock Today – December 8, 2025: Pipeline Bets, Cidara Deal and Vaccine Policy Risks

Merck shares fell about 1% to $98.60 on December 8 after a CDC panel voted to end universal hepatitis B vaccination for newborns. The policy shift raised concerns over future demand for Merck’s Recombivax HB vaccine. The stock remains about 6% below its late-November high of $105.84. Merck’s market cap stands near $250 billion.

8 December 2025

NYSE:MRK·Pharmaceuticals·Stock Market

Recursion Pharmaceuticals (RXRX) Stock Jumps on Positive FAP Trial Data: Latest News, AI Drug Discovery Outlook and Analyst Forecasts

Recursion Pharmaceuticals reported Phase 1b/2 trial data showing its AI-discovered drug REC-4881 reduced polyp burden by a median 43% at 13 weeks in patients with familial adenomatous polyposis. Shares rose as much as 6% pre-market before settling in the mid-$4 range. Most patients maintained or improved reductions after stopping treatment. No approved drugs currently exist for this condition.

8 December 2025

Artificial Intelligence·Biotechnology·NASDAQ:RXRX·Pharmaceuticals

Merck Stock (MRK) Before the Bell on December 8, 2025: Keytruda Setback, $8B Bond Deal and What Investors Should Watch

Merck shares closed at $99.72 on Friday, down 1.16%, with volume above average. The stock sits about 6% below its November 52-week high and trades at roughly 13 times trailing earnings, with a dividend yield of 3.3–3.5%. A German court blocked Merck’s launch of subcutaneous Keytruda, citing patent infringement claims by Halozyme.

8 December 2025

NYSE:MRK·Pharmaceuticals·Stock Market

Eli Lilly (LLY) Stock: Key Catalysts to Watch Before the Market Opens on December 8, 2025

Eli Lilly shares closed Friday at $1,010.31, down 0.41%, before edging higher after hours. The stock sits about 9% below its late-November record high. Over the weekend, China added Lilly’s Alzheimer’s drug Kisunla to a new insurance list for high-priced therapies, offering improved market access with smaller price cuts than usual. Investors await Monday’s session for reaction.

7 December 2025

NYSE:LLY·Pharmaceuticals·Stock Market

Vertex Pharmaceuticals (VRTX) Stock on December 7, 2025: Casgevy Breakthrough, Pain-Drug Setbacks and What 2026 Forecasts Are Saying

Vertex Pharmaceuticals shares closed at $455.48 on December 5, 2025, valuing the company at about $115–116 billion. New data presented December 6 showed CASGEVY gene therapy achieved 12-month crisis- and transfusion-free outcomes in children 5–11 with sickle cell disease and beta thalassemia, though one pediatric patient died from transplant complications. Vertex plans global regulatory filings for this age group in early 2026.

7 December 2025

Biotechnology·NASDAQ:CRSP·NASDAQ:VRTX·Pharmaceuticals·Stock Market

Merck (MRK) Stock Outlook on December 7, 2025: Price Action, Keytruda Setback, Debt Deal and 2026 Analyst Forecasts

Merck closed an $8 billion senior notes offering, likely to help fund its $9.2 billion Cidara Therapeutics acquisition. The company also reported new regulatory wins and raised its dividend, but faced a patent setback for subcutaneous Keytruda in Germany. Merck shares ended December 5 at $99.72, down 1.2%, and remain near the top of their 52-week range. Trading volume was above average.

7 December 2025

Financial Forecasts·NYSE:MRK·Pharmaceuticals·Stock Market

Novo Nordisk Stock (NVO) in December 2025: Alzheimer’s Failure, GLP‑1 Price Cuts and 2026 Turnaround Hopes

Novo Nordisk shares have dropped about 45% in 2025 and over 50% from their 2024 peak, following profit warnings, slower GLP-1 growth, and a failed Alzheimer’s trial. The stock now trades near $47.9, down sharply after the EVOKE and EVOKE+ studies showed no significant benefit for semaglutide in early Alzheimer’s. Revenue in Q3 2025 rose 5% to DKK 74.98 billion, missing analyst expectations.

7 December 2025

NYSE:NVO·Pharmaceuticals·Stock Market

Previous 1 … 27 28 29 30 31 … 38 Next

Jim Cramer Warns of Overconfidence in Market After U.S.-Iran Ceasefire
April 11, 2026, 7:01 AM EDT. CNBC's Jim Cramer cautioned investors that the stock market is "incredibly overconfident" following a sharp rally after the U.S.-Iran ceasefire announcement. The S&P 500 surged 3.6% last week, fueled by President Trump's two-week pause on Iranian strikes. Despite the relief rally, Cramer warned the ceasefire is fragile and the Middle East situation remains precarious, with risks such as the Strait of Hormuz still unresolved. He advised caution, noting no systemic risk but stressing the market's reaction may be premature. Looking ahead, Cramer will focus on upcoming earnings from major banks like Goldman Sachs and Wells Fargo, highlighting Goldman's potential gain from market volatility. He also mentioned Johnson & Johnson's earnings as a stock to watch, given its history of volatility and strong pipeline.

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 11.04.2026

11 April 2026

LIVEMarkets rolling coverageStarted: April 11, 2026, 12:00 AM EDTUpdated: April 11, 2026, 7:09 AM EDT Jim Cramer Warns of Overconfidence in Market After U.S.-Iran Ceasefire April 11, 2026, 7:01 AM EDT. CNBC's Jim Cramer cautioned investors that the stock market is "incredibly overconfident" following a sharp rally after the U.S.-Iran ceasefire announcement. The S&P 500 surged 3.6% last week, fueled by President Trump's two-week pause on Iranian strikes. Despite the relief rally, Cramer warned the ceasefire is fragile and the Middle East situation remains precarious, with risks such as the Strait of Hormuz still unresolved. He advised caution, noting no

Australia Stock Market Today: ASX 200 Ends Lower but Still Logs Best Week Since 2022

10 April 2026

The S&P/ASX 200 fell 0.14% to 8,960.6 on Friday, though it gained about 4.4% for the week, its best since 2022. BHP dropped 1.1%, Fortescue 1.3%, and Santos 0.6%. Telix Pharmaceuticals surged 7.3% after a U.S. regulatory move. Traders await U.S.-Iran talks as Middle East conflict keeps supply and inflation risks in focus.

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026

London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026

Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.

US Stock Market Today: Live Updates 10.04.2026

10 April 2026

LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 11:59 PM EDT Orora ASX:ORA Faces Earnings Reset After Saverglass Impact and Middle East Disruptions April 10, 2026, 11:59 PM EDT. Orora (ASX:ORA) shares plunged over 8% in one day following a guidance update that revealed an earnings reset at its Saverglass unit due to Middle East supply chain disruptions and a shutdown at the Ras Al Khaimah glass plant. Despite a sharp short-term loss, Orora's 90-day share price rise exceeds 33%, contrasting a longer-term 10.58% annual total shareholder return decline amid ongoing sector pressures. Trading at A$1.49,

Go toTop

Pharmaceuticals 7 December 2025 - 10 December 2025

Stock Market Today

Latest article